688373 盟科药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-20.389-74.976-69.243-41.120-26.660
总资产报酬率 ROA (%)-5.637-31.091-43.686-31.593-20.532
投入资产回报率 ROIC (%)-6.770-36.430-49.074-33.692-21.557

边际利润分析
销售毛利率 (%)86.60484.81382.80181.60881.699
营业利润率 (%)-44.878-172.864-333.522-452.655-462.460
息税前利润/营业总收入 (%)-39.806-168.251-323.228-448.462-435.981
净利润/营业总收入 (%)-41.959-170.422-338.306-463.914-456.987

收益指标分析
经营活动净收益/利润总额(%)106.616103.429103.870107.841121.401
价值变动净收益/利润总额(%)-5.914-2.643-3.931-8.032-8.394
营业外收支净额/利润总额(%)-0.0380.2000.0051.024-1.200

偿债能力分析
流动比率 (X)2.1752.7743.5267.71511.906
速动比率 (X)1.9932.5503.2777.44111.716
资产负债率 (%)74.03870.84948.30428.63018.906
带息债务/全部投入资本 (%)56.46554.29430.63213.1129.154
股东权益/带息债务 (%)55.06064.642193.434602.728918.363
股东权益/负债合计 (%)35.06541.145107.021249.282428.927
利息保障倍数 (X)-7.876-33.922-31.344-50.535-20.766

营运能力分析
应收账款周转天数 (天)79.34188.66574.41565.59546.745
存货周转天数 (天)722.594862.647726.712640.488671.209